— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
Electronic Arts (EA) Q4 earnings drop and miss estimates; revenue down 3%
Video game company Electronic Arts, Inc. (NASDAQ: EA) reported lower earnings and revenues for the fourth quarter of 2021. Earnings also missed analysts' forecast. During the March quarter, net bookings
What lies in store for Tyson Foods (TSN) this year?
Shares of Tyson Foods Inc. (NYSE: TSN) were in green territory during afternoon hours on Tuesday. The stock has gained 32% over the past 12 months and 23% since the
Virgin Galactic (SPCE) fails to impress market amid looming uncertainty
Space tourism company Virgin Galactic Holdings, Inc. (NYSE: SPCE) ended the first quarter of 2021 without generating revenue and continued the losing streak even as uncertainty over its test flight
